Rethinking Treatment Strategies in Recurrent Ovarian Cancer
At Great Debates Solid Tumors in Miami, Florida, Rebecca Porter, MD, PhD, from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses whether treatment paradigms for recurrent ovarian cancer should evolve beyond traditional regulatory standards.
Dr Porter highlights emerging therapies including antibody–drug conjugates, taxane combinations, and bispecific antibodies that may reshape treatment strategies, and discusses questions around platinum sensitivity in patients previously treated with PARP inhibitors and the need for prospective data to guide future practice.
Source:
Porter R. Treatment of platinum-sensistive and resistant recurrent ovarian cancer: Optimizing outcomes with currently available therapies– the regulatory standard is the treatment standard vs rethinking recurrent ovarian cancer– ADCs, new taxane combinations, bispecifics– what will the future of treatment selection look like? Presented at Great Debates - Solid Tumors; Miami, Florida. March 14-15, 2026.
